Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Goodwill (Tables)

v3.24.0.1
Goodwill (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill Abstract  
Schedule of Goodwill

For the purpose of impairment testing, goodwill is allocated as follows:

 

 

 

At December 31,

 

 

At December 31,

 

 

 

2023

 

 

2022

 

 

 

(EUR thousand)

 

Biopharmaceutical and Diagnostic Solutions (*)

 

 

31,804

 

 

 

31,804

 

Engineering Systems

 

 

18,179

 

 

 

15,438

 

Total Goodwill

 

 

49,983

 

 

 

47,243

 

(*) For the purpose of the impairment test at December 31, 2022, the goodwill currently allocated to CGU Biopharmaceutical and Diagnostic Solutions amounting to EUR 31,804 thousand was allocated to the CGUs Drug Containment Solutions (DCS) and In-vitro Diagnostic Consumables & Drug Delivery Systems (IVD&DDS) for EUR 4,976 thousand and EUR 26,828 thousand respectively.